Core Viewpoint - Chinese concept stocks experienced significant gains, with notable increases in share prices for several companies, indicating a positive market sentiment towards these stocks [1] Group 1: Top Gainers - Nature's Sunshine Products (UPC) saw a remarkable increase of 82.98%, closing at a price of 9.460, with a trading volume of 235 million [1] - Melco Resorts & Entertainment (MSC) rose by 19.23%, reaching a price of 4.680, with a trading volume of 48,500 [1] - I-Mab (IMAB) increased by 16.02%, closing at 5.070, with a trading volume of 29.76 million [1] - Zai Lab (APM) experienced a gain of 15.31%, closing at 2.410, with a trading volume of 1.6078 million [1] - China Natural Resources (CHNR) rose by 14.84%, closing at 5.700, with a trading volume of 8.8604 million [1]

Merger Agreement and Structure - Aptorum and DiamiR entered into a Merger Agreement on July 14, 2025, with DiamiR becoming a wholly owned subsidiary of Aptorum[65]. - Following the Merger, Aptorum shareholders are expected to own approximately 30% of the outstanding shares of the Combined Company, while DiamiR stockholders are expected to own approximately 70%[69]. - The proposed share consolidation will occur at a ratio of either 2-1, 3-1, or other ratios as determined by the Board[74]. - The Domestication Proposal requires a special resolution with at least two-thirds of the votes cast by Aptorum Class A and Class B shareholders[73]. - The issuance of shares of Aptorum Delaware common stock to DiamiR stockholders will represent more than 20% of the shares outstanding immediately prior to such issuance[77]. - Aptorum plans to change its corporate name to "Niki BioSolutions, Inc." following the Merger[65]. - The approval of the Domestication Proposal is a condition to closing the Merger under the Merger Agreement[73]. - A new stock incentive plan will be implemented with an unspecified number of shares of Common Stock[77]. - Five directors have been proposed for appointment to the Combined Company, effective upon the Closing of the Merger[77]. - The Combined Company board will consist of five members, with three designated by Aptorum and two by DiamiR, including Ian Huen as Chair[88]. - The executive management team post-Merger will include Ian Huen as CEO, Gary Anthony as CFO, and Alidad Mireskandari as President and COO[89]. - The merger agreement includes provisions for DiamiR stockholders to appoint directors to the Combined Company's board, contingent on their ownership percentage[140]. Financial Overview - DiamiR has incurred net losses of $743,235 and $614,405 for the years ended May 31, 2025 and 2024, respectively, with an accumulated deficit of $5,822,571[128]. - DiamiR has raised over $9.7 million in grant funding, including approximately $3.86 million from the NIH for the development of its lead diagnostic product, CogniMIR®[130]. - DiamiR has not generated any revenues from product sales and expects to continue incurring net losses and negative cash flows for the foreseeable future[128]. - DiamiR's valuation at the time of the merger closing is set at $18.7 million, with Aptorum's stock price at $0.94 per share prior to the merger agreement[151]. - The combined company will maintain a cash balance of no less than $2,260,000 and working capital of no less than $1,644,000 at closing, with Aptorum currently holding approximately $2.8 million in cash[174]. - Aptorum has approximately $2.8 million in cash and current assets of approximately $3.0 million as of June 30, 2025, with a target to maintain at least $2,260,000 in unrestricted cash at the closing of the Merger[190]. Strategic Focus and Operations - Aptorum focuses on R&D and has streamlined operations by terminating clinical services and suspending non-lead R&D projects to enhance shareholder value[125]. - Aptorum aims to develop a broad range of therapeutics and diagnostics, focusing on unmet medical needs in oncology and infectious diseases[121]. - The company is actively seeking strategic collaborators to provide financial support and clinical expertise for advancing its therapeutic programs[123]. - Aptorum's lead projects include ALS-4 and SACT-1, with ALS-4 progressing towards IND submission after positive FDA feedback[123]. - The merger is expected to create long-term value through DiamiR's product candidates in brain health, cancer, and inflammatory diseases[153]. - The merger is seen as more favorable than potential alternatives, which could lead to a delisting of Aptorum's Class A ordinary shares from Nasdaq[152]. Regulatory and Approval Considerations - The merger is subject to various conditions, including the approval of the Nasdaq Stock Issuance Proposal and the effectiveness of a registration statement on Form S-4[172]. - The completion of the Merger is subject to regulatory approvals which may delay or prevent consummation[185]. - The Merger will be accounted for under GAAP, with Aptorum as the accounting acquirer and DiamiR as the accounting acquiree[181]. - The time required to obtain approval from regulatory authorities like the FDA and EMA is unpredictable and typically takes many years[244]. - Regulatory authorities may require additional studies or data, delaying approval and commercialization plans for Aptorum's drug candidates[247]. Risks and Challenges - The market price of the Combined Company's shares may decline due to ownership dilution and failure to achieve anticipated benefits from the Merger[196]. - The Combined Company may face significant management challenges and resource allocation issues during the integration process post-Merger[198]. - The company currently does not generate revenue from product sales and may never become profitable without raising additional capital[217]. - The average cost of launching a new drug is estimated to approach $2.6 billion and can take around 12 years to reach the market[221]. - Approximately 86.2% of drug candidates entering phase 1 trials fail to achieve drug approval[221]. - The company has limited financial and managerial resources, focusing on three Lead Projects, which may ultimately prove unsuccessful[227]. - Delays in patient enrollment for clinical trials could result in increased costs and affect the timing or outcome of the trials[233]. - Compliance with current Good Clinical Practices (cGCP) is essential, and failure to comply may render clinical data unreliable[238]. - Clinical trials may be suspended or terminated due to safety issues or non-compliance with regulatory requirements[246]. - Significant clinical trial delays could allow competitors to bring products to market before Aptorum, impairing its commercialization efforts[243]. Management and Governance - Certain officers and directors of Aptorum and DiamiR have interests in the Merger that may differ from those of shareholders, potentially influencing their support for the Merger[194]. - No independent fairness opinion was obtained regarding the Merger, with the consideration reached through negotiations deemed fair by Aptorum's board[195]. - Anti-takeover provisions in the Proposed Charter and Bylaws could make it difficult for stockholders to replace management or initiate beneficial transactions[209]. - The Proposed Charter will designate Delaware courts as the exclusive forum for certain litigation, potentially limiting stockholders' options for judicial recourse[213].

Core Viewpoint - Aptorum Group Limited and DiamiR Biosciences Corp. are collaborating on a merger, with DiamiR set to become a wholly-owned subsidiary of Aptorum, pending shareholder approval and customary closing conditions [3]. Company Overview Aptorum Group - Aptorum Group Limited is a clinical stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutic assets for diseases with unmet medical needs, particularly in oncology and infectious diseases [4]. DiamiR Biosciences - DiamiR is a private molecular diagnostics company that develops minimally invasive tests for early detection and monitoring of brain health conditions and other diseases, utilizing a proprietary platform technology protected by over 50 patents worldwide [5]. Merger Details - The merger between Aptorum and DiamiR was announced on July 16, 2025, and is expected to close in the fourth quarter of 2025, subject to stockholder approval [3]. - DiamiR's CEO, Alidad Mireskandari, will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025 [2].

Core Viewpoint - Chinese concept stocks experienced significant declines, with the top five losers showing steep drops in their stock prices, indicating potential market volatility and investor concerns [1] Group 1: Stock Performance - Dongfang Culture (OCG) saw a decline of 17.19%, closing at 2.890, with a trading volume of 585,300 [1] - Renkong Technology (RCON) dropped by 12.69%, ending at 2.270, with a trading volume of 1,132,700 [1] - Zhiling Group (APM) fell by 11.74%, closing at 2.330, with a trading volume of 6,809,100 [1] - Luda Technology (LUD) decreased by 10.66%, finishing at 5.280, with a trading volume of 75,800 [1] - Dingxin Holdings (DXST) experienced a drop of 10.31%, closing at 1.130, with a trading volume of 60,800 [1]

Group 1 - The top five gainers among Chinese concept stocks include Zhiling Group with a rise of 234.65%, Luda Technology up by 49.89%, Riri Zhu increasing by 28.83%, Heitong Technology gaining 24.14%, and Stark Industrial rising by 20.98% [1][1][1] Group 2 - Zhiling Group's latest price is 4.250 with a gain of 2.980, and a trading volume of 1.282 billion [1][1][1] - Luda Technology's latest price is 6.520 with a gain of 2.170, and a trading volume of 1.0979 million [1][1][1] - Riri Zhu's latest price is 13.450 with a gain of 3.010, and a trading volume of 0.28697 million [1][1][1] - Heitong Technology's latest price is 4.500 with a gain of 0.875, and a trading volume of 0.13155 million [1][1][1] - Stark Industrial's latest price is 1.730 with a gain of 0.300, and a trading volume of 0.45584 million [1][1][1]

Core Insights - Aptorum Group Limited's stock (APM) is experiencing significant trading activity, with a volume of 168.16 million shares compared to the average of 3.25 million shares [1] - DiamiR Biosciences Corp., Aptorum's merger partner, has received approval for its APOE Genotyping test from the New York State Department of Health [1][2] - The merger between Aptorum and DiamiR is expected to close in the fourth quarter of 2025, with DiamiR becoming a wholly owned subsidiary of Aptorum [4] Company Developments - DiamiR's approved APOE Genotyping test will be available for various biological samples, enhancing its market reach through CLIA certified and CAP accredited laboratories [2] - The approval of the APOE Genotyping test is seen as a significant advancement for risk assessment and personalized care strategies for cognitive decline [3] - Aptorum has regained compliance with Nasdaq's minimum bid price requirement, as confirmed in August [3] Stock Performance - APM stock has seen a substantial increase of 148.08%, reaching a price of $3.15 [4]

Core Insights - The stock of APM (知临集团) opened with a significant increase of 123.62%, reaching $2.84 per share, with a trading volume of $253 million and a total market capitalization of $20.2883 million [1] Financial Performance - As of December 31, 2023, APM reported total revenue of $431,400, representing a year-over-year decrease of 66.71% [1] - The company recorded a net loss attributable to shareholders of $2.8246 million, which is an increase of 71.18% compared to the previous year [1] Company Overview - APM is a biopharmaceutical company focused on the research and commercialization of innovative medical and diagnostic technologies to address unmet medical needs [1] - The company's drug development projects target orphan diseases, infectious diseases, and metabolic disorders, with some projects aimed to enter clinical trials by 2020 [1] - APM also operates a women's health product line, with its Dioscorea Opposita bioactive nutritional tablets currently in commercialization [1]

Core Viewpoint - DiamiR Biosciences Corp. has received approval for its APOE Genotyping test from the New York State Department of Health, allowing it to offer this test through its accredited laboratory, which is a significant milestone for the company in expanding its diagnostic capabilities for brain health [1][3][4] Company Overview - DiamiR Biosciences is focused on developing innovative blood-based diagnostic tests for brain health and other diseases, with a particular emphasis on neurodegenerative conditions [1][8] - The company utilizes a proprietary platform technology that analyzes microRNA signatures in plasma for early detection and monitoring of brain health conditions [8] Regulatory Approval - The approval from the New York State Department of Health is part of the Clinical Laboratory Evaluation Program (CLEP), which is known for its stringent validation standards for laboratory-developed tests [2][3] - This approval enables DiamiR to provide its APOE Genotyping test using various biological samples, including blood and saliva, through licensed healthcare providers [1][2] APOE Testing Significance - The APOE test identifies genetic variants linked to the risk of late-onset Alzheimer's disease, with the APOE ε4 allele being the strongest known genetic risk factor [4] - Individuals with one copy of the APOE ε4 allele have a 3-4 times higher risk of developing Alzheimer's, while those with two copies have an 8-12 times higher risk compared to non-carriers [4] Merger Announcement - DiamiR Biosciences and Aptorum Group Limited have entered into a definitive agreement for an all-stock merger, which is expected to close in the fourth quarter of 2025, subject to stockholder approval [6] - Upon completion of the merger, DiamiR will become a wholly-owned subsidiary of Aptorum Group [6] Broader Diagnostic Portfolio - DiamiR's diagnostic portfolio includes tests for monitoring brain health through the analysis of circulating brain-enriched and inflammation-associated microRNAs in blood plasma [5]

Core Points - Aptorum Group Limited has regained compliance with Nasdaq's minimum bid price requirement, confirming that its Class A ordinary shares closed at least $1.00 for 10 consecutive business days prior to the October 14, 2025 deadline [1][2][3] - The closing bid price was maintained at $1.00 or greater from July 16, 2025 to July 30, 2025, leading to the closure of the compliance matter by Nasdaq [2][3] - Aptorum Group announced an all-stock merger with DiamiR Biosciences, which will become a wholly-owned subsidiary upon completion of the transaction [4] Company Overview - Aptorum Group Limited is a clinical stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutic assets for diseases with unmet medical needs, particularly in oncology and infectious diseases [5] - DiamiR Biosciences specializes in developing minimally invasive tests for early detection and monitoring of brain health conditions and other diseases, utilizing a proprietary platform technology based on microRNA signatures [6]

Core Viewpoint - Aptorum Group Limited has announced a definitive agreement for an all-stock merger with DiamiR Biosciences, which will become a wholly-owned subsidiary of Aptorum, retaining its name and continuing to be listed on the Nasdaq Stock Market after the merger [1][4]. Company Overview - Aptorum Group is a clinical stage biopharmaceutical company focused on addressing unmet medical needs in oncology and infectious diseases [8]. - DiamiR Biosciences specializes in developing proprietary blood-based tests for brain health and other diseases, operating a CLIA licensed, CAP accredited clinical laboratory [1][9]. Merger Details - The merger will involve Aptorum re-domiciling to Delaware and acquiring all outstanding capital stock of DiamiR in exchange for shares representing approximately 70% of the combined company's common stock, with current Aptorum equity holders retaining 30% [3][4]. - The merger agreement has been approved by the boards of both companies and is subject to stockholder approval and customary closing conditions, with an expected closing in the fourth quarter of 2025 [4][6]. Leadership and Structure - Post-merger, the combined company will be headquartered in Princeton, New Jersey, with Ian Huen as CEO, Dr. Alidad Mireskandari as President and COO, and Gary Anthony as CFO [5]. - The board of directors will consist of five members, with three designated by Aptorum and two by DiamiR [5]. Strategic Goals - The merger aims to create a global life sciences company capable of generating revenue through biopharma services and offering biomarker panels for complex-biology indications, particularly in aging-related diseases and brain health [2][3]. - DiamiR's expertise in assay development and commercialization is expected to enhance the combined company's capabilities in non-invasive blood-based testing [2].